Yu Kaku a, †
Contributed equally
, Kaho Okumura a, f, †
Contributed equally
, Miguel Padilla-Blanco g, h, Yusuke Kosugi a, b, Keiya Uriu a, b, Alfredo A Hinay a, Luo Chen a, i, Arnon Plianchaisuk a, Kouji Kobiyama c, d, Ken J Ishii c, d, The Genotype to Phenotype Japan (G2P-Japan) Consortium
Jiri Zahradnik
g, Jumpei Ito
a, e, Kei Sato
a, b, d, e, i, j, k a Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113–8654, Japan
b Graduate School of Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo 113–8654, Japan
c Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113–8654, Japan
d International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 113–8654, Japan
e International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 113–8654, Japan
f Faculty of Liberal Arts, Sophia University, Tokyo, Japan
g First Medical Faculty at Biocev, Charles University, Prague, Czechia
h Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain
i Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
j Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan
k CREST, Japan Science and Technology Agency, Kawaguchi, Japan